Please assess the completion status of the following clinical trial:

Trial Title: Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has type 2 diabetes mellitus (T2DM)~* Patient is 18 years of age (or older)~* Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period~Exclusion Criteria:~* Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis~* Patient required insulin within the prior 8 weeks~* Patient is on a weight loss program and is not in the maintenance phase~* Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the prior 8 weeks~* Patient is on or likely to require treatment with treatment with immunosuppressive agents (e.g., cyclosporin, methotrexate)~* Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic gallbladder disease~* Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder (e.g., multiple sclerosis or polymyositis)~* Patient has any of the following disorders within the past 6 months:~Acute coronary syndrome (e.g., MI or unstable angina), Coronary artery intervention, Stroke or transient ischemic neurological disorder.~* Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months~* Patient has severe peripheral vascular disease~* Patient has congestive heart failure~* Patient is HIV positive~* Patient has a clinically important hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)~* Patient has a history of neoplastic disease~* Patient has a history of alcohol or drug abuse within the past 3 years~* Patient has viral hepatitis (hepatitis B or C)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 100 mg (Type: ACTIVE_COMPARATOR): Sitagliptin 100 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).